AMY RUDDICK: Open Payments
NPI 1013581685 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,307 in 117 payments from 15 companies in 2025. Trend: 2023 $3,032 · 2024 $2,617 · 2025 $2,307
Food & beverage: $2,223Education: $84
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 41 | $738 |
| Madrigal Pharmaceuticals | 15 | $243 |
| Janssen Biotech, Inc. | 8 | $218 |
| Gilead Sciences, Inc. | 11 | $202 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $192 |
| GENZYME CORPORATION | 5 | $152 |
| Ipsen Biopharmaceuticals, Inc | 6 | $135 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $104 |
| Celltrion USA Inc. | 4 | $67 |
| Lilly USA, LLC | 3 | $66 |
Products named: CREON, REZDIFFRA, RINVOQ, TREMFYA, DUPIXENT, LINZESS, IQIRVO, ENTYVIO.
Industry payments across NE — which companies pay providers there.
